NCT03824561Completed
Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]
Special Drug-Use Surveillance Study on Entyvio for IV Infusion 300 mg [Ulcerative Colitis]
Source: ClinicalTrials.gov · Last updated 11 Sept 2025
Brief summary (registry, in English)
The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in ulcerative colitis (UC) patients in the routine clinical setting.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1110 (actual)
- First submitted
- 29 Jan 2019
- Start date
- 1 Feb 2019
- Primary completion date
- 12 Feb 2025
- Lead sponsor
- Takeda
- Diseases
- Ulcerative colitis
- NCT number
- NCT03824561
What you commit to
- Study type: Observational
- Participants enrolled: 1110
- From 1 Feb 2019 to the primary completion date, 12 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients with any contraindication for vedolizumab
Who the study is looking for
- Have moderate or severe active UC
- Have inadequate response to existing therapies
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.